

## Temozolomide Injection Formulation

Version 9.1      Revision Date: 2023/09/26      SDS Number: 27565-00024      Date of last issue: 2023/03/20  
Date of first issue: 2014/11/03

---

### 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Temozolomide Injection Formulation

#### Manufacturer or supplier's details

Company : MSD

Address : JL Raya Pandaan KM. 48  
Pandaan, Jawa Timur - Indonesia

Telephone : 908-740-4000

Emergency telephone number : 1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

#### Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

---

### 2. HAZARDS IDENTIFICATION

#### GHS Classification

Acute toxicity (Oral) : Category 3

Serious eye damage/eye irritation : Category 2A

Germ cell mutagenicity : Category 2

Carcinogenicity : Category 2

Reproductive toxicity : Category 1B

Specific target organ toxicity - repeated exposure (Oral) : Category 2 (Bone marrow, thymus gland, Lymph nodes, spleen)

#### GHS label elements

Hazard pictograms :



Signal word : Danger

Hazard statements : H301 Toxic if swallowed.  
H319 Causes serious eye irritation.

## Temozolomide Injection Formulation

Version 9.1      Revision Date: 2023/09/26      SDS Number: 27565-00024      Date of last issue: 2023/03/20  
Date of first issue: 2014/11/03

H341 Suspected of causing genetic defects.  
H351 Suspected of causing cancer.  
H360FD May damage fertility. May damage the unborn child.  
H373 May cause damage to organs (Bone marrow, thymus gland, Lymph nodes, spleen) through prolonged or repeated exposure if swallowed.

Precautionary statements :

**Prevention:**

P201 Obtain special instructions before use.  
P202 Do not handle until all safety precautions have been read and understood.  
P260 Do not breathe dust.  
P264 Wash skin thoroughly after handling.  
P270 Do not eat, drink or smoke when using this product.  
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

**Response:**

P301 + P310 + P330 IF SWALLOWED: Immediately call a POISON CENTER/ doctor. Rinse mouth.  
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.  
P308 + P313 IF exposed or concerned: Get medical advice/ attention.  
P337 + P313 If eye irritation persists: Get medical advice/ attention.

**Storage:**

P405 Store locked up.

**Disposal:**

P501 Dispose of contents/ container to an approved waste disposal plant.

**Other hazards which do not result in classification**

Contact with dust can cause mechanical irritation or drying of the skin.  
May form explosive dust-air mixture during processing, handling or other means.

### 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

**Components**

Chemical name	CAS-No.	Concentration (% w/w)
Citric acid	77-92-9	>= 10 -< 20
Temozolomide	85622-93-1	>= 1 -< 10

### 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical ad-

## Temozolomide Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/03/20
9.1	2023/09/26	27565-00024	Date of first issue: 2014/11/03

---

		vice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	:	If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	:	In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	:	In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention.
If swallowed	:	If swallowed, DO NOT induce vomiting. Call a physician or poison control centre immediately. Rinse mouth thoroughly with water. Never give anything by mouth to an unconscious person.
Most important symptoms and effects, both acute and delayed	:	Toxic if swallowed. Causes serious eye irritation. Suspected of causing genetic defects. Suspected of causing cancer. May damage fertility. May damage the unborn child. May cause damage to organs through prolonged or repeated exposure if swallowed. Contact with dust can cause mechanical irritation or drying of the skin.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	:	Treat symptomatically and supportively.

### 5. FIREFIGHTING MEASURES

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO <sub>2</sub> ) Dry chemical
Unsuitable extinguishing media	:	None known.
Specific hazards during fire-fighting	:	Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion products	:	Carbon oxides Nitrogen oxides (NO <sub>x</sub> ) Metal oxides Chlorine compounds
Specific extinguishing method	:	Use extinguishing measures that are appropriate to local cir-

## Temozolomide Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/03/20
9.1	2023/09/26	27565-00024	Date of first issue: 2014/11/03

---

ods

cumstances and the surrounding environment.  
 Use water spray to cool unopened containers.  
 Remove undamaged containers from fire area if it is safe to do so.  
 Evacuate area.

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
 Use personal protective equipment.

---

### 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.  
 Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.  
 Prevent further leakage or spillage if safe to do so.  
 Retain and dispose of contaminated wash water.  
 Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.  
 Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).  
 Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.  
 Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
 Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

---

### 7. HANDLING AND STORAGE

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.  
 Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling : Do not get on skin or clothing.  
 Do not breathe dust.  
 Do not swallow.  
 Do not get in eyes.  
 Wash skin thoroughly after handling.  
 Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
 Keep container tightly closed.  
 Minimize dust generation and accumulation.

---

## Temozolomide Injection Formulation

Version 9.1      Revision Date: 2023/09/26      SDS Number: 27565-00024      Date of last issue: 2023/03/20  
 Date of first issue: 2014/11/03

Keep container closed when not in use.  
 Keep away from heat and sources of ignition.  
 Take precautionary measures against static discharges.  
 Do not eat, drink or smoke when using this product.  
 Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage : Keep in properly labelled containers.  
 Store locked up.  
 Keep tightly closed.

Materials to avoid : Store in accordance with the particular national regulations.  
 Do not store with the following product types:  
 Explosives

### 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Temozolomide	85622-93-1	TWA	0.1 ug/m3 (OEB 5)	Internal
		Wipe limit	1 µg/100 cm2	Internal

**Engineering measures** : Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace.  
 All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.  
 No open handling permitted.  
 Totally enclosed processes and materials transport systems are required.  
 Operations require the use of appropriate containment technology designed to prevent leakage of compounds into the workplace.

#### Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.  
 If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
 Wear a faceshield or other full face protection if there is a

## Temozolomide Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/03/20
9.1	2023/09/26	27565-00024	Date of first issue: 2014/11/03

---

Skin and body protection	:	<p>potential for direct contact to the face with dusts, mists, or aerosols.</p> <p>Work uniform or laboratory coat.</p> <p>Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.</p> <p>Use appropriate degowning techniques to remove potentially contaminated clothing.</p>
Hygiene measures	:	<p>If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.</p> <p>When using do not eat, drink or smoke.</p> <p>Wash contaminated clothing before re-use.</p> <p>The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.</p>

---

### 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	powder
Colour	:	white
Odour	:	No data available
Odour Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	Not applicable
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	Not applicable

**Temozolomide Injection Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2023/03/20
9.1	2023/09/26	27565-00024	Date of first issue: 2014/11/03

---

Relative vapour density	:	Not applicable
Relative density	:	No data available
Density	:	No data available
Solubility(ies)	:	
Water solubility	:	soluble
Partition coefficient: n-octanol/water	:	Not applicable
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity	:	
Viscosity, kinematic	:	Not applicable
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle size	:	No data available

---

**10. STABILITY AND REACTIVITY**

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

---

**11. TOXICOLOGICAL INFORMATION**

Information on likely routes of exposure	:	Inhalation Skin contact Ingestion Eye contact
------------------------------------------	---	--------------------------------------------------------

**Acute toxicity**

Toxic if swallowed.

**Temozolomide Injection Formulation**

Version 9.1      Revision Date: 2023/09/26      SDS Number: 27565-00024      Date of last issue: 2023/03/20  
Date of first issue: 2014/11/03

---

**Product:**

Acute oral toxicity : Acute toxicity estimate: 243.59 mg/kg  
Method: Calculation method

**Components:****Citric acid:**

Acute oral toxicity : LD50 (Mouse): 5,400 mg/kg

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg  
Method: OECD Test Guideline 402  
Assessment: The substance or mixture has no acute dermal toxicity

**Temozolomide:**

Acute oral toxicity : LD50 (Dog): 19 mg/kg  
LD50 (Rat): 315 mg/kg  
LD50 (Mouse): 205 mg/kg

**Skin corrosion/irritation**

Not classified based on available information.

**Components:****Citric acid:**

Species : Rabbit  
Method : OECD Test Guideline 404  
Result : No skin irritation

**Serious eye damage/eye irritation**

Causes serious eye irritation.

**Components:****Citric acid:**

Species : Rabbit  
Result : Irritation to eyes, reversing within 21 days  
Method : OECD Test Guideline 405

**Respiratory or skin sensitisation****Skin sensitisation**

Not classified based on available information.

**Respiratory sensitisation**

Not classified based on available information.



**Temozolomide Injection Formulation**

Version 9.1      Revision Date: 2023/09/26      SDS Number: 27565-00024      Date of last issue: 2023/03/20  
Date of first issue: 2014/11/03

---

**Components:****Temozolomide:**

Test Type : Maximisation Test  
Exposure routes : Dermal  
Species : Guinea pig  
Result : negative

**Germ cell mutagenicity**

Suspected of causing genetic defects.

**Components:****Citric acid:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: in vitro micronucleus test  
Result: positive

Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow  
cytogenetic test, chromosomal analysis)  
Species: Rat  
Application Route: Ingestion  
Result: negative

**Temozolomide:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: positive

Test Type: Chromosome aberration test in vitro  
Test system: Human lymphocytes  
Result: positive

Germ cell mutagenicity - Assessment : Positive results from in vitro mammalian mutagenicity assays,  
chemical structure activity relationship to known germ cell  
mutagens

**Carcinogenicity**

Suspected of causing cancer.

**Components:****Temozolomide:**

Species : Rat  
Application Route : Oral  
Exposure time : 6 Months  
: 4 mg/kg body weight

## Temozolomide Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/03/20
9.1	2023/09/26	27565-00024	Date of first issue: 2014/11/03

---

Result : positive  
Target Organs : Mammary gland

Carcinogenicity - Assessment : Limited evidence of carcinogenicity in animal studies

### Reproductive toxicity

May damage fertility. May damage the unborn child.

### Components:

#### Citric acid:

Effects on foetal development : Test Type: One-generation reproduction toxicity study  
Species: Rat  
Application Route: Ingestion  
Result: negative

#### Temozolomide:

Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Rat, male  
Application Route: Oral  
Fertility: LOAEL: 8.5 mg/kg body weight  
Result: positive

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Oral  
Embryo-foetal toxicity: LOAEL: 13 mg/kg body weight  
Result: positive, Malformations were observed.

Reproductive toxicity - Assessment : Clear evidence of adverse effects on sexual function and fertility, based on animal experiments., Clear evidence of adverse effects on development, based on animal experiments.

### STOT - single exposure

Not classified based on available information.

### Components:

#### Citric acid:

Assessment : May cause respiratory irritation.

### STOT - repeated exposure

May cause damage to organs (Bone marrow, thymus gland, Lymph nodes, spleen) through prolonged or repeated exposure if swallowed.

### Components:

#### Temozolomide:

Exposure routes : Ingestion  
Target Organs : Bone marrow, thymus gland, Lymph nodes, spleen  
Assessment : Causes damage to organs through prolonged or repeated

**Temozolomide Injection Formulation**

Version 9.1      Revision Date: 2023/09/26      SDS Number: 27565-00024      Date of last issue: 2023/03/20  
Date of first issue: 2014/11/03

---

exposure.

**Repeated dose toxicity****Components:****Citric acid:**

Species : Rat  
NOAEL : 4,000 mg/kg  
LOAEL : 8,000 mg/kg  
Application Route : Ingestion  
Exposure time : 10 Days

**Temozolomide:**

Species : Rat, female  
NOAEL : 4 mg/kg  
LOAEL : 21 mg/kg  
Application Route : Oral  
Exposure time : 6 Months  
Target Organs : Lymph nodes, thymus gland, Bone marrow, Reproductive organs

Species : Rat, male  
NOAEL : 8.5 mg/kg  
LOAEL : 34 mg/kg  
Application Route : Oral  
Exposure time : 6 Months  
Target Organs : Lymph nodes, thymus gland, Bone marrow, male reproductive organs, Gastrointestinal tract

Species : Dog  
NOAEL : 2.5 mg/kg  
LOAEL : 6.3 mg/kg  
Application Route : Oral  
Exposure time : 6 Months  
Target Organs : Bone marrow, spleen, male reproductive organs, Gastrointestinal tract, thymus gland

**Aspiration toxicity**

Not classified based on available information.

**Experience with human exposure****Components:****Temozolomide:**

Ingestion : Symptoms: Blood disorders, Nausea, Vomiting, Diarrhoea, anorexia, Fatigue, hair loss

**Temozolomide Injection Formulation**

Version 9.1      Revision Date: 2023/09/26      SDS Number: 27565-00024      Date of last issue: 2023/03/20  
Date of first issue: 2014/11/03

---

**12. ECOLOGICAL INFORMATION****Ecotoxicity****Components:****Citric acid:**

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l  
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 1,535 mg/l  
Exposure time: 24 h

**Temozolomide:**

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 90 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 40 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201

Toxicity to microorganisms : EC50: > 100 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

**Persistence and degradability****Components:****Citric acid:**

Biodegradability : Result: Readily biodegradable.  
Biodegradation: 97 %  
Exposure time: 28 d  
Method: OECD Test Guideline 301B

**Temozolomide:**

Biodegradability : Result: rapidly degradable  
Biodegradation: 83 %

## Temozolomide Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/03/20
9.1	2023/09/26	27565-00024	Date of first issue: 2014/11/03

---

Exposure time: 35 d

Stability in water : Degradation half life (DT50): < 1 d

### Bioaccumulative potential

#### Components:

##### Citric acid:

Partition coefficient: n-octanol/water : log Pow: -1.72

##### Temozolomide:

Partition coefficient: n-octanol/water : log Pow: 1.35

#### Mobility in soil

No data available

#### Other adverse effects

No data available

---

## 13. DISPOSAL CONSIDERATIONS

### Disposal methods

Waste from residues : Do not dispose of waste into sewer.  
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

---

## 14. TRANSPORT INFORMATION

### International Regulations

#### UNRTDG

UN number : Not applicable  
Proper shipping name : Not applicable  
Class : Not applicable  
Subsidiary risk : Not applicable  
Packing group : Not applicable  
Labels : Not applicable

#### IATA-DGR

UN/ID No. : Not applicable  
Proper shipping name : Not applicable  
Class : Not applicable  
Subsidiary risk : Not applicable  
Packing group : Not applicable  
Labels : Not applicable  
Packing instruction (cargo aircraft) : Not applicable

**Temozolomide Injection Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2023/03/20
9.1	2023/09/26	27565-00024	Date of first issue: 2014/11/03

---

Packing instruction (passenger aircraft) : Not applicable

**IMDG-Code**

UN number : Not applicable  
Proper shipping name : Not applicable  
Class : Not applicable  
Subsidiary risk : Not applicable  
Packing group : Not applicable  
Labels : Not applicable  
EmS Code : Not applicable  
Marine pollutant : Not applicable

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

**Special precautions for user**

Not applicable

---

**15. REGULATORY INFORMATION****Safety, health and environmental regulations/legislation specific for the substance or mixture**

**Minister of Industry Regulation No. 23/M-IND/PER/4/2013 concerning the Revision of Minister of Industry Regulation No. 87/M-IND/PER/9/2009 concerning Globally Harmonized System of Classification and Labelling of Chemicals.**

**Regulation of the Minister of Health No. 472 of 1996 on the Safeguarding of Substances Hazardous to Health**

Hazardous substances that must be registered : Not applicable

**Government Regulation No. 74 of 2001 on the Management of Hazardous and Toxic Substances**

Hazardous substances approved for use : Not applicable

Prohibited substances : Not applicable

Restricted substances : Not applicable

**Regulation of the Ministry of Trade No. 7 of 2022 on Distribution and Control of Hazardous Materials**

Type of hazardous materials subject to distribution and control, Annex I : Not applicable

Type of hazardous materials subject to distribution and control, Annex II : Not applicable

**The components of this product are reported in the following inventories:**

AICS : not determined

---

## Temozolomide Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/03/20
9.1	2023/09/26	27565-00024	Date of first issue: 2014/11/03

---

DSL : not determined

IECSC : not determined

---

### 16. OTHER INFORMATION

Revision Date : 2023/09/26

#### Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Date format : yyyy/mm/dd

#### Full text of other abbreviations

AllC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for

## Temozolomide Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/03/20
9.1	2023/09/26	27565-00024	Date of first issue: 2014/11/03

---

safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ID / EN